Synthesis, and biological evaluation of novel 4-thiazolidinone derivatives as promising antidiabetic agents: In silico and in vivo investigations
- 12 August 2026
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 834, 154436
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort StudyHepatology, 2021
- Rosiglitazone ameliorates skeletal muscle insulin resistance by decreasing free fatty acids release from adipocytesBiochemical and Biophysical Research Communications, 2020
- The antidiabetic drug lobeglitazone has the potential to inhibit PTP1B activityBioorganic Chemistry, 2020
- Novel hybrids of benzothiazole-1,3,4-oxadiazole-4-thiazolidinone: Synthesis, in silico ADME study, molecular docking and in vivo anti-diabetic assessmentBioorganic Chemistry, 2019
- Global trends in diabetes complications: a review of current evidenceDiabetologia, 2018
- The role and regulation of the peroxisome proliferator activated receptor alpha in human liverBiochimie, 2017
- Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to presentEuropean Journal of Medicinal Chemistry, 2017
- Study of novel anticancer 4-thiazolidinone derivativesChemico-Biological Interactions, 2017
- Derivatives of benzimidazole pharmacophore: Synthesis, anticonvulsant, antidiabetic and DNA cleavage studiesEuropean Journal of Medicinal Chemistry, 2010
- PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndromeCurrent Opinion in Pharmacology, 2006